• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Epidemiol Infect . Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley

tetano

Editor, Senior Moderator
Epidemiol Infect


. 2021 Aug 3;149:e194.
doi: 10.1017/S0950268821001886.
Prevalence and determinants of serum antibodies to SARS-CoV-2 in the general population of the Gardena valley


Roberto Melotti[SUP] 1 [/SUP], Federica Scaggiante[SUP] 2 [/SUP], Michela Falciani[SUP] 3 [/SUP], Christian X Weichenberger[SUP] 1 [/SUP], Luisa Foco[SUP] 1 [/SUP], Stefano Lombardo[SUP] 4 [/SUP], Alessandro De Grandi[SUP] 1 [/SUP], Dorothee von Laer[SUP] 5 [/SUP], Angelika Mahlknecht[SUP] 6 7 [/SUP], Peter P Pramstaller[SUP] 1 [/SUP], Elisabetta Pagani[SUP] 8 [/SUP], Horand Meier[SUP] 9 [/SUP], Timon Gaertner[SUP] 4 [/SUP], Christina Troi[SUP] 2 [/SUP], Deborah Mascalzoni[SUP] 1 10 [/SUP], Cristian Pattaro[SUP] 1 [/SUP], Michael Mian[SUP] 11 12 [/SUP]



Affiliations

Abstract

Estimating the spread of SARS-CoV-2 infection in communities is critical. We surveyed 2244 stratified random sample community members of the Gardena valley, a winter touristic area, amidst the first expansion phase of the COVID-19 pandemic in Europe. We measured agreement between Diasorin and Abbott serum bioassay outputs and the Abbott optimal discriminant threshold of serum neutralisation titres with recursive receiver operating characteristic curve. We analytically adjusted serum antibody tests for unbiased seroprevalence estimate and analysed the determinants of infection with non-response weighted multiple logistic regression. SARS-CoV-2 seroprevalence was 26.9% (95% CI 25.2-28.6) by June 2020. The bioassays had a modest agreement with each other. At a lower threshold than the manufacturer's recommended level, the Abbott assay reflected greater discrimination of serum neutralisation capacity. Seropositivity was associated with place and economic activity, not with sex or age. Symptoms like fever and weakness were age-dependent. SARS-CoV-2 mitigation strategies should account for context in high prevalence areas.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; neutralising antibodies; prevalence.
 
Back
Top Bottom